OR-NUSCALE-POWER
12.5.2023 16:16:26 CEST | Business Wire | Press release
NuScale Power Corporation (NYSE: SMR) announced today the opening of a NuScale Energy Exploration Center (E2 Center) at University Politehnica of Bucharest in support of a collaboration with the United States and Romanian governments, and S.N. Nuclearelectrica S.A. (Nuclearelectrica). Key government officials attended the opening, including U.S. Ambassador to Romania Kathleen Kavalec, Romania Prime Minister Nicolae Ciuca, and Romanian Minister of Energy Virgil Popescu. As the first international E2 Center, this workforce development tool will enable Romania to develop the next generation of advanced nuclear experts, technologists, and operators and become a hub for deploying small modular reactors (SMR) in Europe.
“NuScale’s SMR nuclear technology is the premier global clean energy solution and can help advance Romania’s position as a leader in the secure and safe deployment of SMRs,” said John Hopkins, NuScale President and Chief Executive Officer. “With the support of the DOS under the FIRST program, we are thrilled to hit another milestone in this remarkable collaboration among our countries and organizations. We look forward to supporting the next generation of clean energy leaders across the region and around the globe.”
The E2 Center was funded by the U.S. Department of State (DOS) under the Foundational Infrastructure for the Responsible Use of Small Modular Reactor Technology (FIRST) program. FIRST supports partner countries in advancing their nuclear energy programs to meet their clean energy goals under the highest international standards for nuclear safety, security, and nonproliferation.
"The SMR project at Doicesti, which this E2 Center supports, will showcase Romanian leadership in energy innovation, accelerate the clean energy transition, create thousands of jobs in Romania and the U.S., and strengthen European energy security while upholding the highest standards for nuclear safety, security, and nonproliferation,” said Ann Ganzer, Principal Deputy Assistant Secretary, Bureau of International Security and Nonproliferation.
This announcement builds upon NuScale Power and Nuclearelectrica’s teaming agreement signed in 2021 to deploy a 462 MWe NuScale VOYGRTM-6 power plant in Romania by the end of the decade. Earlier this year, NuScale and RoPower Nuclear S.A. (RoPower), owned in equal shares by Nuclearelectrica and Nova Power & Gas S.A., commenced front-end engineering and design work for a site in Doicesti, Romania, the preferred location for the deployment of the VOYGR power plant.
Romania has the potential to be one of the first deployments of an SMR in Europe and to become a catalyst for SMRs in the region by serving as a base for supporting operations of this new technology in other countries, as well as the production and assembly of plant components.
“Building on the strong nuclear experience in safe operations for more than 26 years, we are proud to support Romania’s workforce development in the nuclear sector for a new technologically advanced future. Nuclearelectrica has outstanding specialists and operational performance, and is internationally recognized, which not only places Romanian nuclear industry as a top performer, but also as the foundation for Romania’s leadership in nuclear energy. Nuclearelectrica has strong assets, which qualifies us to be the first country after the U.S. to deploy a NuScale SMR. The first E2 Center launched in Romania is only the beginning of this new era in technology, human resources, safe, affordable clean energy, with multiple benefits for communities and industries, to which we are happy to contribute,” Cosmin Ghita, Chief Executive Officer of Nuclearelectrica.
“Nuclear energy and SMRs are included in Romania’s energy strategy as a main pillar for energy security and reaching our decarbonation targets. Our commitment to increase energy production from clean nuclear energy sources will create much needed complementarity with renewable resources, increase flexibility in the system, and allow further complex development of former coal-based facilities. The 26 years of Romanian safe operation expertise are the basis for further developing Romania’s nuclear energy program. The energy transition is not possible without maintaining and expanding the role of nuclear power and it requires strong international partnerships, like the one we are enhancing today. I thank our American partners for their continuous support, Nuclearelectrica for its leadership in the industry and capability to take on the journey to become a regional preferred operator, and University of Politehnica for their dedication towards performance and workforce development. I want to give a clear message: The Romanian Prime Minister Nicolae Ciuca, our Government, and Romanian President Klaus Iohannis strongly support the development of nuclear energy and the effort to form experts in this domain,” said Virgil Popescu, Minister of Energy, Romania.
The E2 Center is an innovative learning environment that offers users a hands-on opportunity to apply nuclear science and engineering principles through simulated, real-world nuclear power plant operation scenarios. The E2 Center employs state-of-the-art computer modeling to simulate a NuScale VOYGR SMR power plant control room. Users have the opportunity to take on the role of a “Control Room Operator” at a VOYGR plant to learn about the advanced operational and safety features unique to NuScale’s technology.
The University Politehnica of Bucharest is one of the elite schools of the Romanian higher education system. The school was established in 1950, and offers highly appreciated academic studies and programs for more than 2,000 students a year.
About NuScale Power
NuScale Power Corporation (NYSE: SMR) is the industry-leading provider of proprietary and innovative advanced small modular reactor nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. The company’s groundbreaking VOYGR™ SMR plants are powered by the NuScale Power Module™, a small, safe, pressurized water reactor that can each generate 77 megawatts of electricity (MWe) or 250 megawatts thermal (gross), and can be scaled to meet customer needs through an array of flexible configurations up to 924 MWe (12 modules) of output.
As the first and only SMR to have its design certified by the U.S. Nuclear Regulatory Commission, NuScale is well-positioned to serve diverse customers across the world by supplying nuclear energy for electrical generation, district heating, desalination, commercial-scale hydrogen production, and other process heat applications.
Founded in 2007, NuScale is headquartered in Portland, Ore. To learn more, visit NuScale Power’s website or follow us on Twitter, Facebook, LinkedIn, Instagram and YouTube.
Forward Looking Statements
This release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. These forward-looking statements are inherently subject to risks, uncertainties and assumptions. Actual results may differ materially as a result of a number of factors. Caution must be exercised in relying on these and other forward-looking statements. Due to known and unknown risks, NuScale’s results may differ materially from its expectations and projections. NuScale specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NuScale’s assessments as of any date subsequent to the date of this release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005176/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
